Peer-influenced content. Sources you trust. No registration required. This is HCN.
Oncology News Central (ONC)
In the fast-evolving landscape of oncology treatment, a new study reveals oncologists’ unique stance on FDA approval processes, emphasizing the importance of timely access to potentially life-saving drugs despite conventional evidentiary standards.
Hematology/Oncology February 20th 2024
MDLinx
This study underscores the critical need for precise diagnostic criteria in treating unexplained strokes and the potential reevaluation of anticoagulant use in patients with atrial cardiopathy, opening new avenues for research and patient care.
Neurology February 13th 2024
Psychiatrist.com
Lamotrigine stands out for its efficacy in preventing depressive episodes in bipolar I disorder, offering a nuanced option for mood stabilization with an antidepressant emphasis. Understanding its specific clinical applications can enhance treatment strategies for mood disorders.
Clinical Pharmacology February 13th 2024
The New England Journal of Medicine
In a recent trial, late administration of tenecteplase, from 4.5 to 24 hours post-stroke onset, did not demonstrate a significant advantage over placebo in improving the functional outcomes of patients, as measured by the modified Rankin scale at 90 days.
Cancer Therapy Advisor
Recent findings from the ASCO Gastrointestinal Cancers Symposium 2024 underscore the potential of innovative therapeutic combinations in enhancing outcomes for hepatocellular carcinoma patients, particularly those with unresectable or high-risk disease.
Oncology, Medical February 12th 2024
Dana-Farber Cancer Institute
In the landmark KEYNOTE-564 trial, pembrolizumab has emerged as a pivotal advancement in kidney cancer treatment, offering hope by significantly prolonging survival in patients with high-risk ccRCC post-nephrectomy.